Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. said the Food and Drug Administration has accepted for review their new drug application for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). With a standard 10-month review, a target action date of June 2012 is expected.
For more from BostonGlobe.com, sign up or log in below
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Get FREE access as part of your print subscription.
Click to continue reading this article or to log in to BostonGlobe.com.